General term referring to either a trivalent or pentavalent antimony complex with sodium gluconate. Pentavalent compound may require reduction in vivo to the trivalent form to be bioactive. Determn in biological materials and pharmacodynamics: R. J. Ward et al., Clin. Chim. Acta 99, 143 (1979). Mechanism of action study: J. C. Mottram, G. H. Coombs, Exp. Parasitol. 59, 151 (1985).
Trivalent antimony compound. Prepn: Das Gupta, Indian J. Pharm. 15, 84 (1953); A. Axon et al., US 3306921 (1967 to Burroughs Wellcome). Antiparasitic activity: N. Ercoli et al., Chemotherapy 26, 254 (1980).
Pentavalent antimony compound. Prepn: Datta, Ghosh, Sci. Cult. 11, 699 (1945-6); Bose, Ghosh, Indian J. Pharm. 11, 155 (1949). Pharmacokinetics: J. D. Chulay et al., Trans. R. Soc. Trop. Med. Hyg. 82, 69 (1988). Review of clinical safety and efficacy in leishmaniasis: B. L. Herwaldt, J. D. Berman, Am. J. Trop. Med. Hyg. 46, 296 (1992).
Trivalent compd as an anthelmintic (Schistosoma); pentavalent compd as an antiprotozoal (Leishmania).
Sodium Antimonylgluconate: Anthelmintic (Schistosoma)
Sodium Stibogluconate: Antiprotozoal (Leishmania)